Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

THIM Hogeschool voor Fysiotherapie heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL. Heb je een vraag, neem dan contact op met helpdesk@thim.nl.

» Andere revante producten voor THIM studenten en medewerkers.

Registreer

Om ook buiten de locaties van THIM, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van THIM.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Netherlands Heart Journal
Gepubliceerd in:

01-11-2007 | Original article

Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial

Auteurs: J. W. van Werkum, W. B. M. Gerritsen, J. C. Kelder, C. M. Hackeng, S. M. Ernst, V. H. M. Deneer, M. J. Suttorp, B. J. W. M. Rensing, H. W. M. Plokker, J. M. ten Berg

Gepubliceerd in: Netherlands Heart Journal | Uitgave 11/2007

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Extract

Platelet activation is pivotal in the pathogenesis of acute myocardial infarction (AMI) and in the occurrence of complications after percutaneous coronary interventions (PCI).1 In the Netherlands, primary PCI is the preferred reperfusion strategy in the treatment of ST-segment elevation myocardial infarction (STEMI) and recent studies in advancing the treatment of STEMI include the use of GP IIb/IIIa receptor inhibitors.2-5 Most data relate to abciximab, which has been registered for this indication. Specifically, the ADMIRAL (Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term followup) trial showed that early administration of abciximab in patients with STEMI improves coronary patency, left ventricular function and clinical outcomes.4 However, data about the use of tirofiban in the setting of STEMI are limited. In the On-Time (ONgoing Tirofiban In Myocardial infarction Evaluation) study, tirofiban started before hospitalisation did not improve TIMI III flow compared with tirofiban started after angiography.5 …
vorige artikel Long-term prognostic value of CFVR and FFR versus perfusion scintigraphy in patients with multivessel disease
volgende artikel Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents
Literatuur
1.
Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262-75.
2.
Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341:1413-9.
3.
Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346: 957-66.
4.
Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al., for the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2002; 344:1895-903.
5.
Van ’t Hof AWJ, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, et al., for the On-TIME study group. Facilitation of primary coronary angioplasty by early start of glycoprotein IIb/IIIa inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004;25:837-46.
6.
The TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94.
7.
Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, Aggarwal A, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002;90:1421-4.
8.
Soffer D, Moussa I, Karatepe M, Harjai KJ, Boura J, Dixon SR, et al. Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris. Am J Cardiol 2003;91:872-5.
9.
Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002;89:647-50.
10.
Lakkis NM, George S, Thomas E, Ali M, Guyer K, Carville D. Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors. Catheter Cardiovasc Interv 2001;53:346-51.
11.
Siotia A, Buckland R, Judge HM, Sastry P, Storey RF. Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention. Thromb Haemost 2006;95:997-1002.
12.
Ernst NM, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JC, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004;44:1187-93.
13.
Mammen EF, Comp PC, Gosselin R C, Greenberg C, Hoots WK, Kessler CM, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.
14.
Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488-94.
15.
Marciniak SJ Jr, Jordan RE, Mascelli MA. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thromb Haemost 2001;85:539-43.
16.
Scarborough RM, Kleiman NS Philips DR. Platelet Glycoprotein IIb/IIIa Antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100:437-44.
17.
The EPIC Investigaters. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
18.
Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001;103:2572-8.
19.
Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with chimeric 7E3 Fab: implications for inhibition of the internal pool of GP IIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665-71.
20.
Schror K, Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003;15:71-80.
21.
Cook NS, Kottirsch G, Zerwes H-G. Platelet glycoprotein IIb/IIIa antagonists. Drugs Future 1994;19:135-59.
22.
Matzdorff A, Voss R. Upregulation of GP IIb/IIIa receptors during platelet activation: Influence on efficacy of receptor blockade. Thromb Res 2006;117:307-14.
23.
Matzdorff AC, Kühnel G, Kemkes-Matthes B, Comparison of GP IIb/IIIa inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer. J Thromb Thrombolysis 2001;12:129-39.
24.
Renda G, Rocca B, Crocchiolo R, De Cristofaro R, Landolfi R. Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban Thromb Haemost 2003;89:348-54.
Metagegevens
Titel
Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial
Auteurs
J. W. van Werkum
W. B. M. Gerritsen
J. C. Kelder
C. M. Hackeng
S. M. Ernst
V. H. M. Deneer
M. J. Suttorp
B. J. W. M. Rensing
H. W. M. Plokker
J. M. ten Berg
Publicatiedatum
01-11-2007
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 11/2007
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03086018

Andere artikelen Uitgave 11/2007

Images in cardiovascular medicine: Transkei heart

  • Imaging in cardiology

Coronary stent healing, endothelialisation and the role of co-medication

  • Interuniversity Cardiology Institute of the Netherlands

Long-term prognostic value of CFVR and FFR versus perfusion scintigraphy in patients with multivessel disease

  • Original article

Transvenous pacing after the Mustard procedure: considering the complications

  • Case report

Does glycoprotein IIB/IIIA resistance exist?

  • Editorial

Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents

  • Original article